Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression

William R. Harrington, Shubin Sheng, Daniel H. Barnett, Larry N. Petz, John A. Katzenellenbogen, Benita S Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

Estrogens exert their regulatory transcriptional effects, which can be stimulatory or repressive, at diverse gene sites via two estrogen receptors, ERα and ERβ. Since these two ERs have different tissue distributions, ligands that have the capacity to selectively activate or inhibit these two ERs would be useful in elucidating the biology of these two receptors and might assist in the development of estrogen pharmaceuticals with improved tissue selectivity. We have developed several ligands that showed ERα or ERβ selectivity at promoter-gene sites containing consensus estrogen response elements (EREs): ERα-selective agonist (propyl-pyrazole-triol (PPT)), ERα-selective antagonist (methyl-piperidino-pyrazole (MPP)), ERβ-potency selective agonist (diarylpropionitrile (DPN)) and ERβ-selective antagonist/ERα-agonist (R,R-tetrahydrochrysene (R,R-THC)). In this study, we have examined the activity of these compounds at a range of gene sites where ER stimulates gene expression through non-consensus EREs (complement C3), or multiple half-EREs (NHE-RF/EBP50), or by tethering to DNA via other proteins (TGF β3 and progesterone receptor A/AP-1), and at gene sites where ER represses gene transcription (interleukin-6). At all of these genes, PPT showed full stimulation through ERα while displaying no agonism through ERβ. MPP antagonized estradiol actions on gene transactivation and transrepression through ERα, with little or no effect on transcription mediated through ERβ. DPN displayed subtype-selective agonism, being ca. 30-fold more potent through ERβ. R,R-THC was a complete antagonist through ERβ and displayed agonism through ERα, the level of which was promoter dependent. Because these ligands maintain their agonist or antagonist character and ER subtype-selectivity at gene sites of diverse nature, where estradiol is either stimulatory or inhibitory, these compounds should prove useful in elucidating the biological functions of ERα and ERβ.

Original languageEnglish (US)
Pages (from-to)13-22
Number of pages10
JournalMolecular and Cellular Endocrinology
Volume206
Issue number1-2
DOIs
StatePublished - Aug 29 2003

Fingerprint

Estrogen Receptor beta
Estrogen Receptor alpha
Transcriptional Activation
Estrogens
Genes
Ligands
Response Elements
Transcription
Estradiol
Tissue
Complement C3
Transcription Factor AP-1
Tissue Distribution
Gene expression
Estrogen Receptors
Interleukin-6
Gene Expression
DNA

Keywords

  • Estrogen receptors
  • Subtype selective ligands
  • Transactivation
  • Transrepression

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Cite this

Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. / Harrington, William R.; Sheng, Shubin; Barnett, Daniel H.; Petz, Larry N.; Katzenellenbogen, John A.; Katzenellenbogen, Benita S.

In: Molecular and Cellular Endocrinology, Vol. 206, No. 1-2, 29.08.2003, p. 13-22.

Research output: Contribution to journalArticle

Harrington, William R. ; Sheng, Shubin ; Barnett, Daniel H. ; Petz, Larry N. ; Katzenellenbogen, John A. ; Katzenellenbogen, Benita S. / Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. In: Molecular and Cellular Endocrinology. 2003 ; Vol. 206, No. 1-2. pp. 13-22.
@article{f7a2aac879b7495cbf2bdcd176f4e040,
title = "Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression",
abstract = "Estrogens exert their regulatory transcriptional effects, which can be stimulatory or repressive, at diverse gene sites via two estrogen receptors, ERα and ERβ. Since these two ERs have different tissue distributions, ligands that have the capacity to selectively activate or inhibit these two ERs would be useful in elucidating the biology of these two receptors and might assist in the development of estrogen pharmaceuticals with improved tissue selectivity. We have developed several ligands that showed ERα or ERβ selectivity at promoter-gene sites containing consensus estrogen response elements (EREs): ERα-selective agonist (propyl-pyrazole-triol (PPT)), ERα-selective antagonist (methyl-piperidino-pyrazole (MPP)), ERβ-potency selective agonist (diarylpropionitrile (DPN)) and ERβ-selective antagonist/ERα-agonist (R,R-tetrahydrochrysene (R,R-THC)). In this study, we have examined the activity of these compounds at a range of gene sites where ER stimulates gene expression through non-consensus EREs (complement C3), or multiple half-EREs (NHE-RF/EBP50), or by tethering to DNA via other proteins (TGF β3 and progesterone receptor A/AP-1), and at gene sites where ER represses gene transcription (interleukin-6). At all of these genes, PPT showed full stimulation through ERα while displaying no agonism through ERβ. MPP antagonized estradiol actions on gene transactivation and transrepression through ERα, with little or no effect on transcription mediated through ERβ. DPN displayed subtype-selective agonism, being ca. 30-fold more potent through ERβ. R,R-THC was a complete antagonist through ERβ and displayed agonism through ERα, the level of which was promoter dependent. Because these ligands maintain their agonist or antagonist character and ER subtype-selectivity at gene sites of diverse nature, where estradiol is either stimulatory or inhibitory, these compounds should prove useful in elucidating the biological functions of ERα and ERβ.",
keywords = "Estrogen receptors, Subtype selective ligands, Transactivation, Transrepression",
author = "Harrington, {William R.} and Shubin Sheng and Barnett, {Daniel H.} and Petz, {Larry N.} and Katzenellenbogen, {John A.} and Katzenellenbogen, {Benita S}",
year = "2003",
month = "8",
day = "29",
doi = "10.1016/S0303-7207(03)00255-7",
language = "English (US)",
volume = "206",
pages = "13--22",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression

AU - Harrington, William R.

AU - Sheng, Shubin

AU - Barnett, Daniel H.

AU - Petz, Larry N.

AU - Katzenellenbogen, John A.

AU - Katzenellenbogen, Benita S

PY - 2003/8/29

Y1 - 2003/8/29

N2 - Estrogens exert their regulatory transcriptional effects, which can be stimulatory or repressive, at diverse gene sites via two estrogen receptors, ERα and ERβ. Since these two ERs have different tissue distributions, ligands that have the capacity to selectively activate or inhibit these two ERs would be useful in elucidating the biology of these two receptors and might assist in the development of estrogen pharmaceuticals with improved tissue selectivity. We have developed several ligands that showed ERα or ERβ selectivity at promoter-gene sites containing consensus estrogen response elements (EREs): ERα-selective agonist (propyl-pyrazole-triol (PPT)), ERα-selective antagonist (methyl-piperidino-pyrazole (MPP)), ERβ-potency selective agonist (diarylpropionitrile (DPN)) and ERβ-selective antagonist/ERα-agonist (R,R-tetrahydrochrysene (R,R-THC)). In this study, we have examined the activity of these compounds at a range of gene sites where ER stimulates gene expression through non-consensus EREs (complement C3), or multiple half-EREs (NHE-RF/EBP50), or by tethering to DNA via other proteins (TGF β3 and progesterone receptor A/AP-1), and at gene sites where ER represses gene transcription (interleukin-6). At all of these genes, PPT showed full stimulation through ERα while displaying no agonism through ERβ. MPP antagonized estradiol actions on gene transactivation and transrepression through ERα, with little or no effect on transcription mediated through ERβ. DPN displayed subtype-selective agonism, being ca. 30-fold more potent through ERβ. R,R-THC was a complete antagonist through ERβ and displayed agonism through ERα, the level of which was promoter dependent. Because these ligands maintain their agonist or antagonist character and ER subtype-selectivity at gene sites of diverse nature, where estradiol is either stimulatory or inhibitory, these compounds should prove useful in elucidating the biological functions of ERα and ERβ.

AB - Estrogens exert their regulatory transcriptional effects, which can be stimulatory or repressive, at diverse gene sites via two estrogen receptors, ERα and ERβ. Since these two ERs have different tissue distributions, ligands that have the capacity to selectively activate or inhibit these two ERs would be useful in elucidating the biology of these two receptors and might assist in the development of estrogen pharmaceuticals with improved tissue selectivity. We have developed several ligands that showed ERα or ERβ selectivity at promoter-gene sites containing consensus estrogen response elements (EREs): ERα-selective agonist (propyl-pyrazole-triol (PPT)), ERα-selective antagonist (methyl-piperidino-pyrazole (MPP)), ERβ-potency selective agonist (diarylpropionitrile (DPN)) and ERβ-selective antagonist/ERα-agonist (R,R-tetrahydrochrysene (R,R-THC)). In this study, we have examined the activity of these compounds at a range of gene sites where ER stimulates gene expression through non-consensus EREs (complement C3), or multiple half-EREs (NHE-RF/EBP50), or by tethering to DNA via other proteins (TGF β3 and progesterone receptor A/AP-1), and at gene sites where ER represses gene transcription (interleukin-6). At all of these genes, PPT showed full stimulation through ERα while displaying no agonism through ERβ. MPP antagonized estradiol actions on gene transactivation and transrepression through ERα, with little or no effect on transcription mediated through ERβ. DPN displayed subtype-selective agonism, being ca. 30-fold more potent through ERβ. R,R-THC was a complete antagonist through ERβ and displayed agonism through ERα, the level of which was promoter dependent. Because these ligands maintain their agonist or antagonist character and ER subtype-selectivity at gene sites of diverse nature, where estradiol is either stimulatory or inhibitory, these compounds should prove useful in elucidating the biological functions of ERα and ERβ.

KW - Estrogen receptors

KW - Subtype selective ligands

KW - Transactivation

KW - Transrepression

UR - http://www.scopus.com/inward/record.url?scp=0042934090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042934090&partnerID=8YFLogxK

U2 - 10.1016/S0303-7207(03)00255-7

DO - 10.1016/S0303-7207(03)00255-7

M3 - Article

C2 - 12943986

AN - SCOPUS:0042934090

VL - 206

SP - 13

EP - 22

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1-2

ER -